Related Experiment Videos
Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia
1Department of Medicine, Oregon Health Sciences University, Portland 97201.
Insights
New HMG CoA reductase inhibitors offer a promising therapy for hypercholesterolemia. These drugs effectively lower LDL cholesterol, potentially reducing the risk of premature atherosclerosis in patients unresponsive to diet alone.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Biochemistry
Background:
- Hypercholesterolemia, characterized by elevated LDL cholesterol, is a significant risk factor for premature coronary atherosclerosis.
- Familial hypercholesterolemia exemplifies the severe consequences of genetic lipid disorders.
- Dietary interventions are often insufficient for managing hypercholesterolemia.
Purpose of the Study:
- To review the therapeutic potential of HMG CoA reductase inhibitors for hypercholesterolemia.
- To evaluate the efficacy and potency of lovastatin, simvastatin, and pravastatin.
- To explore combination therapy strategies for enhanced lipid-lowering effects.
Main Methods:
- Review of clinical trial data and therapeutic experience with HMG CoA reductase inhibitors.
- Comparison of the relative potency of lovastatin, simvastatin, and pravastatin.
- Assessment of combination therapy with bile acid sequestrants and nicotinic acid.
Main Results:
- HMG CoA reductase inhibitors, including lovastatin and simvastatin, are effective in lowering plasma LDL cholesterol by 30% to 50%.
- Simvastatin demonstrates potentially greater potency compared to lovastatin and pravastatin.
- Combination therapy can potentiate the hypocholesterolemic effects of these inhibitors.
Conclusions:
- Specific HMG CoA reductase inhibitors represent a major therapeutic advance for hypercholesterolemia.
- These drugs offer the potential to significantly reduce the incidence of premature atherosclerosis.
- Long-term safety data are crucial for establishing the full clinical utility of these agents.
Abstract:
Hypercholesterolemia with increased plasma concentrations of low density lipoproteins (LDL) is a major risk factor for the premature development of coronary atherosclerosis in humans and is best exemplified by patients with familial hypercholesterolemia. The recent development of several specific competitive inhibitors of the rate-limiting enzyme in cholesterol biosynthesis (3-hydroxy-3-methylglutaryl-coenzyme A reductase, HMG CoA reductase) has opened up an important new avenue of therapy for patients with hypercholesterolemia who are not responsive to dietary treatment alone. Three drugs, lovastatin (mevinolin), simvastatin (synvinolin) and pravastatin (CS 514), are currently undergoing clinical trials in North America and Europe; the former has recently been approved for general use. Experience with lovastatin and simvastatin in the treatment of patients with primary and secondary causes of hypercholesterolemia is reviewed. The relative potency of simvastatin appears to be greater than that of lovastatin and pravastatin but, with each drug, decreases in the plasma concentrations of LDL cholesterol of 30% to 50% can be achieved. The hypocholesterolemic effects of HMG CoA reductase inhibitors can be potentiated by combination therapy with other approved lipid-lowering medications including the bile acid sequestrants and nicotinic acid. If long-term safety can be satisfactorily established, specific inhibitors of HMG CoA reductase represent a major advance in the therapy of hypercholesterolemia and afford the potential to reduce substantially the high incidence of premature atherosclerosis that occurs in patients with persistent hypercholesterolemia.